ADDEX THERAPEUTICS SA NAM.-AKTIE
ADDEX THERAPEUTICS SA NAM.-AKTIE/ CH0029850754 /
A0MSH6
11.09.2024 15:32:57
|
Изменение
-0.005
|
Объем сделки |
Бид15:32:57 |
Предложение15:32:57 |
Рыночная капитализация |
Дивидендная доходность |
Коэффициент Цена/Доход |
0.075EUR
|
-6.52%
|
- Оборот: - |
0.075Величина цены спроса: - |
0.079Величина цены предложения: - |
13.37 млнEUR |
- |
- |
Описание деятельности
Addex Therapeutics (formerly Addex Pharmaceuticals Ltd.) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex' allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline has been generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID. In parallel, dipraglurant's therapeutic use in dystonia is being investigated. Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) program was awarded a $5.3 million grant by the US National Institute on Drug Abuse (NIDA, a division of National Institutes of Health (NIH)) to support human studies in cocaine addiction and has been licensed to Indivior. Discovery programs include mGluR4PAM, mGluR7NAM, mGluR3PAM and TrkBPAM.
Правление & Наблюдательный совет
Исполнительный директор |
Tim Dyer |
Правление |
Lénaïc Teyssédou, Mikhail Kalinichev, Roger G. Mills |
Наблюдательный совет |
Dr. Vincent Lawton, Issac Manke, Jake Nunn, Raymond Hill |
Данные компании
Имя: |
Addex Therapeutics Ltd |
Адрес: |
12 Chemin des Aulx,CH-1228 Plan-les-Ouates / Geneva |
Телефон: |
+41-22-884-1555 |
Факс: |
+41-22-884-1556 |
E-mail: |
info@addextherapeutics.com
|
Интернет: |
www.addextherapeutics.com |
Индустрия: |
Healthcare |
Сектор: |
Medical Products |
Подсектор: |
Advanced Medical Devices |
Конец финансового года: |
31.12 |
Акции в свободном обращении: |
38.48% |
Дата IPO: |
22.05.2007 |